Category: 3. Business

  • Telford and Wrekin Council ‘ahead’ on climate change target

    Telford and Wrekin Council ‘ahead’ on climate change target

    Efforts by Telford and Wrekin Council to reduce its carbon emissions are ahead of target but further reductions are becoming “more challenging”, according to the authority.

    In 2019 the council was among many authorities to declare a “climate emergency” and set out a target to become carbon neutral by 2030.

    A council report said that by the end of March 2025, emissions had been reduced by 63% since 2018/19, thanks to a range of measures in homes, leisure centres, and offices. The authority said that put it eight per cent ahead of where it was expecting to be at this stage.

    The council has set itself a target of reaching a 70 per cent reduction by 2026/27.

    “We have made strong progress in reducing the council’s emissions so far, but we recognise that it is getting harder and more challenging to do,” the report stated.

    Measures taken include making homes more energy-efficient and increasing the number of solar panels on council buildings.

    The council owns the Wheat Leasows solar farm which last year produced 3,144 MWh of electricity, enough energy to power 1,084 homes.

    It said it was looking at the possibility of more solar energy and improving connections to the national electricity network.

    In addition, the authority said it was taking measures to prepare the area for the impact of climate change.

    It said risks included damage to roads and trees from flooding, heat and wind, with heat also recognised as a threat to public health and the smooth running of IT systems.

    Continue Reading

  • Oil prices forecast to ease in 2026 under pressure from ample supply – Reuters

    1. Oil prices forecast to ease in 2026 under pressure from ample supply  Reuters
    2. Five energy market trends to track in 2026, the year of the glut  Reuters
    3. Oil Prices Set to Decline in 2026 amid Oversupply and Ukraine Ceasefire Hopes  Hungary Today
    4. The great electron race  Latitude Media
    5. Rystad Energy: Key predictions in energy for 2026  safety4sea

    Continue Reading

  • Key Shareholder Activism Trends to Watch in 2026 – The Harvard Law School Forum on Corporate Governance

    1. Key Shareholder Activism Trends to Watch in 2026  The Harvard Law School Forum on Corporate Governance
    2. Activist investors set record number of campaigns in 2025, Barclays data shows  Reuters
    3. PepsiCo stock back in the activist spotlight as Barclays flags record campaigns — what investors watch next  ts2.tech
    4. Activist investors set record number of campaigns in 2025, Barclays data shows By Reuters  Investing.com

    Continue Reading

  • Health organisations raise concerns over AI summaries on search engines

    Health organisations raise concerns over AI summaries on search engines

    With the rise of AI summaries for health information and the introduction of AI mode, a group of health charities, including the BHF, have raised concerns about access to trustworthy information. 

    The charities, including end of life charity Marie Curie, the Patient Information Forum (PIF), Macmillan Cancer Support, Cancer Research UK and us, have urged the public to look beyond AI health summaries and visit trusted, evidence-based, UK-verified sources for additional information and context.

    A report from Marie Curie, Macmillan and PIF, which represents health organisations, published earlier this year raised concerns over AI-generated health summaries on search engines such as Google.

    Concerns highlighted by organisations include:

    • Gynae cancer charity The Eve Appeal highlighted that a search for ‘vaginal cancer symptoms and tests’ produced an AI summary that listed a PAP test as a test for vaginal cancer, which is incorrect.     
    • An AI-generated summary advised people with pancreatic cancer to avoid high-fat foods. However, Pancreatic Cancer UK said this advice is the opposite of recommendations for people affected by pancreatic cancer. 
    • Searches for information on what a ‘normal’ range is for liver blood tests returned AI-generated summaries which don’t account for a person’s sex, age or ethnicity. The British Liver Trust said this made the information inaccurate for some people.

    These concerns arise as a recent survey of PIF members revealed that almost half (49%) have seen inaccuracies or misinformation about their topic area in AI overviews.

    More than 6 out of 10 health charities have observed a decline in traffic to their websites since the rollout of health summaries.

    This has sparked concerns that the public is not accessing source information and could be missing out on vital additional professional support and context when it is most needed. 

    The coalition is calling on Google and other search engine providers to take immediate action to reduce potential harm, including:

    • Clear signposting to NHS-approved advice and support services
    • Prioritised verified UK-based sources with links to further information
    • Clear disclaimers that AI-generated content cannot substitute medical advice.

    Dr Charmaine Griffiths, our Chief Executive, said: “Being diagnosed with cardiovascular disease is one of those moments in life where having access to need reliable, evidence-based information and advice is priceless.

    “Each year millions of heart patients and their families turn to the internet in search of answers to their questions, and we have a duty as a society to ensure they access only the highest quality information and advice online.

    “This is why it is so vital that verified sources such as the BHF website remain a first port of call for those in need of trustworthy, unbiased and accurate information about heart disease.” 

    Sophie Randall, Director of the Patient Information Forum, said: “We know there are concerns about the results in some AI Overview results. PIF has a mission to promote trusted health information to the public, which is why we are making our report available to the public. 

    “To stay safe when searching for health information online, we encourage the public to use trusted sources such as www.nhs.uk, look for the PIF TICK, the UK’s only quality mark for reliable health content, and add ‘UK’ to their searches to help surface relevant, UK-based information.” 

    HOW WE CREATE OUR HEALTH INFORMATION

    Continue Reading

  • UK weather latest: Schools closed, trains cancelled and flights delayed as snow hits

    UK weather latest: Schools closed, trains cancelled and flights delayed as snow hits

    The latest UK weather forecast: Snow flurries to ease but cold days aheadpublished at 10:03 GMT

    Sarah Keith-Lucas
    Broadcast Meteorologist, BBC Weather

    Cold Arctic air remains
    across all parts of the UK today.

    Further snow showers are
    expected for areas exposed to the northerly winds, especially northern
    Scotland, Northern Ireland, west Wales, south-west England and parts of eastern
    England.

    The Met Office has issued various yellow warnings for snow and ice warnings
    in these regions.

    While many places will
    stay dry with wintry sunshine, it will feel cold with icy stretches for all.
    Maximum temperatures will reach just -2C across parts of Scotland, and
    typically 1 to 3C elsewhere.

    Most snow flurries will
    gradually ease away later this afternoon and evening, to leave a cold
    night with a sharp frost and ice.

    Tuesday will turn a
    little milder, but further hill snow is possible over the higher ground of
    Scotland and northern England.

    Later in the day and through the night, another
    area of rain, sleet and hill snow will affect the southern half of the UK.

    Any
    snowfall by Tuesday is not expected to be as heavy or disruptive as it has been
    over the past few days.

    As a reminder, you can check the forecast for your area on BBC Weather.

    Continue Reading

  • Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity

    Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity

    Agreement supports development and commercialization of higher-dose, subcutaneous administration strategies for nimacimab

    SAN DIEGO, Jan. 5, 2026 /PRNewswire/ — Halozyme Therapeutics, Inc. (Nasdaq: HALO) and Skye Bioscience, Inc. (Nasdaq: SKYE) today announced the companies entered into a non-exclusive global collaboration and license agreement in December 2025. Under the collaboration, Skye has licensed Halozyme’s ENHANZE® drug delivery technology for the development and potential commercialization of a subcutaneous formulation of nimacimab for the treatment of obesity. The collaboration is intended to support Skye’s evaluation of higher nimacimab subcutaneous doses through delivery of larger injection volumes.

    “Our collaboration with Skye Bioscience expands the reach of our ENHANZE technology into the growing obesity market, a therapeutic area with significant long-term potential,” said Dr. Helen Torley, President and Chief Executive Officer of Halozyme. “This agreement reinforces the scalability of ENHANZE across diverse indications and supports our strategy to drive sustainable royalty growth with new partnerships and innovations.”

    “To fully evaluate nimacimab’s potential, we need to test higher doses and we need a practical way to deliver them subcutaneously,” said Punit Dhillon, President and Chief Executive Officer of Skye. “Partnering with Halozyme to co-formulate nimacimab with ENHANZE gives us a validated approach to evaluate multiple dose-ranging strategies, including in combination with GLP-1 receptor agonists.”

    Skye will make milestone payments tied to the achievement of certain development and commercialization events. Halozyme will also be entitled to mid-single digit royalties on net sales of nimacimab developed with ENHANZE® for at least 10 years.

    Skye is planning to initiate a Phase 2b clinical trial in obesity for nimacimab with ENHANZE in the middle of 2026. This study will also assess the combination of nimacimab and a GLP-1R agonist.

    About Halozyme

    Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies.

    As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme’s commercially validated solution facilitates the subcutaneous delivery of injected drugs and fluids, reducing treatment burden and improving convenience. ENHANZE® has touched more than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, and Merus N.V.

    Halozyme is also developing Hypercon™ to expand the breadth of its drug delivery technology portfolio. Hypercon™ is an innovative microparticle technology that is expected to set a new standard in hyper concentration of drugs and biologics that can reduce the injection volume for the same dosage and expands opportunities for at-home and health care provider administration. The addition of Hypercon™ enhances our ability to transform the patient treatment experience by enabling the creation and delivery of highly concentrated biologics, substantially broadening the scope of therapeutics that can be delivered subcutaneously. The Hypercon™ technology has been licensed to leading biopharmaceutical partners, including Johnson & Johnson, Eli Lilly, and argenx.

    Halozyme also develops, manufactures, and commercializes drug-device combination products using advanced auto-injector technologies designed to improve convenience, reliability, and tolerability, enhancing patient comfort and adherence. The Company has two proprietary commercial products, Hylenex® and XYOSTED®, partnered commercial products, and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.

    Halozyme is headquartered in San Diego, CA, with offices in Ewing, NJ; Minnetonka, MN; and Boston, MA. Minnetonka is also the site of its operations facility.

    For more information, visit http://www.halozyme.com and connect with us on LinkedIn and Twitter.

    About Skye Bioscience

    Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye’s strategy leverages biologic targets with substantial human proof of mechanism for the development of potential first-in-class therapeutics with potential clinical and commercial differentiation. Skye is conducting a Phase 2a clinical trial (ClinicalTrials.gov: NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: www.skyebioscience.com. Connect with us on X and LinkedIn.

    Forward-Looking Statements 

    In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning royalty revenue growth, potential new partnerships and innovations, the possible activity, benefits and attributes of ENHANZE®, the possible method of action of ENHANZE®, its potential application to aid in the dispersion and absorption of other injected therapeutic drugs and statements concerning certain other potential benefits of ENHANZE® including facilitating more rapid delivery and administration of larger volumes of injectable medications through subcutaneous delivery and potentially lowering the treatment burden and improving the treatment experience for patients. These forward-looking statements also include statements regarding the product development and commercialization efforts of Skye (including the potential regulatory approval and launch of nimacimab as a result of such efforts and the potential future market opportunity for such products) and Halozyme’s potential receipt of payments associated with achievement of certain development, regulatory and sales-based milestones, and royalties on sales of commercialized products. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words “believe,” “enable,” “may,” “will,” “could,” “intends,” “estimate,” “anticipate,” “plan,” “predict,” “probable,” “potential,” “possible,” “should,” “continue” and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including risks and uncertainties concerning whether development, regulatory and sales-based milestones will be achieved, uncertainties concerning whether collaborative products are ultimately developed, approved or commercialized and the potential future market for such products, unexpected levels of revenue growth, expenditures and costs, unexpected results or delays in development and regulatory review, unexpected regulatory approval requirements, unexpected adverse events or patient outcomes and competitive conditions. These and other factors that may result in differences are discussed in greater detail in Halozyme and Skye’s most recent Annual and Quarterly Reports filed with the Securities and Exchange Commission. Except as required by law, Halozyme and Skye undertake no duty to update forward-looking statements to reflect events after the date of this release.

    Contacts

    Halozyme
    Tram Bui
    VP, Investor Relations and Corporate Communications
    609-359-3016
    [email protected]

    Skye Investor & Media Relations
    [email protected]
    (858) 410-0266

    LifeSci Advisors
    Mike Moyer
    [email protected]
    (617) 308-4306

    SOURCE Halozyme Therapeutics, Inc.

    Continue Reading

  • BD Marks Milestone with First Phasix™ Hernia Prevention Case in Greece and Over 85% Enrollment in U.S. PREVENT Trial

    BD Marks Milestone with First Phasix™ Hernia Prevention Case in Greece and Over 85% Enrollment in U.S. PREVENT Trial

    BD Marks Milestone with First Phasix™ Hernia Prevention Case in Greece and Over 85% Enrollment in U.S. PREVENT Trial

    FRANKLIN LAKES, N.J., Jan. 5, 2026 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced a significant milestone in its advanced tissue regeneration strategy: the first Phasix™ Mesh laparotomy reinforcement case performed in Greece following the product’s expanded indication for prophylactic use in Europe. This marks the first broad prophylactic indication of hernia mesh across open, high-risk procedures in the European Union.

    The procedure was completed at George Papanikolaou General Hospital of Thessaloniki, one of the largest institutions in northern Greece, led by general surgeon and Associate Professor, Ioannidis Orestis. The patient, a 63-year-old male with multiple risk factors, underwent a sigmoidectomy, and a Phasix™ Mesh (08 x 30 cm) was placed prophylactically at the laparotomy incision site to reduce the likelihood of future hernia development.

    Concurrently, BD’s PREVENT multicenter randomized controlled trial, conducted across sites in both Europe and the United States, has treated over 85% of its target population and is projected to complete enrollment in 2026. The study aims to provide robust clinical evidence supporting prophylactic bioabsorbable mesh placement to reduce the incidence of incisional hernias, while also supporting PMA submission for an incisional hernia prevention indication in the United States.

    “Incisional hernias affect up to 30% of patients after abdominal surgery and cost health care systems billions annually,” said Rian Seger, worldwide president of the BD Surgery business. “With Phasix™ Mesh, we’re not just repairing hernias—we’re preventing them. This milestone reflects our commitment to improving long-term patient outcomes.”

    According to recent U.K. data, patients who undergo incisional hernia repair incur an average cost of £23,148—nearly double that of patients who do not require repair. Prevention strategies have the potential to significantly reduce these costs and improve patient quality of life.

    Phasix™ Mesh received CE marking approval for the prophylactic indication and launched three new sizes in 2025. The product is now registered in the U.K. and available across Europe for broad hernia prophylaxis indications, marking a pivotal step toward redefining surgical best practices, helping clinicians deliver safer outcomes and improve efficiency in every procedure. Phasix™ Mesh is not indicated for use for hernia prevention in the United States.

    About BD

    BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson

     

    BD (Becton, Dickinson and Company) Logo (PRNewsfoto/BD (Becton, Dickinson and Company))

    SOURCE BD (Becton, Dickinson and Company)


    Continue Reading

  • LYB to discuss fourth-quarter results Friday, Jan. 30, 2026

    LYB to discuss fourth-quarter results Friday, Jan. 30, 2026

    HOUSTON and LONDON, Jan. 05, 2026 (GLOBE NEWSWIRE) — LyondellBasell (NYSE: LYB), a leader in the global chemical industry, will announce its fourth-quarter 2025 financial results before the U.S. market opens Friday, Jan. 30, followed by a webcast and teleconference to discuss the results at 11 a.m. EST.

    Teleconference and webcast details
    Friday, January 30, 2026
    11 a.m. EST
    Hosted by David Kinney, head of investor relations
    Access the webcast 10 to 15 minutes prior to the start of the call at www.lyb.com/earnings.

    Toll-free teleconference dial-in numbers
    Participant/Guest toll-free: 877-407-8029
    Participant/Guest toll: 201-689-8029
    Participant/Guest: CallMe link

    Presentation slides
    Presentation slides will be available at the time of the teleconference and afterward at www.lyb.com/earnings.

    Replay information
    A replay of the call will be available from 1 p.m. EST Jan. 30 until March 2, 2026. The replay dial-in numbers are:
    Toll-Free: 877-660-6853
    Toll: 201-612-7415
    Access ID: 13746215

    About LyondellBasell 
    We are LyondellBasell (NYSE: LYB) – a leader in the global chemical industry creating solutions for everyday sustainable living. Through advanced technology and focused investments, we are enabling a circular and low carbon economy. Across all we do, we aim to unlock value for our customers, investors and society. As one of the world’s largest producers of polymers and a leader in polyolefin technologies, we develop, manufacture and market high-quality and innovative products for applications ranging from sustainable transportation and food safety to clean water and quality healthcare. For more information, please visit www.lyondellbasell.com or follow @LyondellBasell on LinkedIn.

    CONTACT: Nick Facchin
    LyondellBasell
    713-623-3643
    nick.facchin@lyondellbasell.com
    


    Continue Reading

  • White & Case advises BasePoint Capital on acquisition of International Personal Finance

    White & Case advises BasePoint Capital on acquisition of International Personal Finance

    Global law firm White & Case LLP has advised BasePoint Capital on its approximately £543 million recommended cash acquisition of International Personal Finance plc (IPF), a leading provider of consumer credit products in international markets.

    The transaction was announced pursuant to Rule 2.7 of the UK Takeover Code and will be implemented by way of a court-sanctioned scheme of arrangement. Completion of the acquisition remains subject to customary shareholder and regulatory approvals.

    “This transaction represents a significant public M&A acquisition in the financial services sector, involving complex structuring, financing and regulatory considerations across multiple jurisdictions,” said White & Case partner Philip Broke, who co-led the Firm’s deal team. Partner Sonica Tolani, who also co-led the team said “Advising BasePoint Capital on this landmark transaction builds on our strong track record advising clients on high-profile UK public takeovers and financial services related M&A.”

    The White & Case team in London which advised on the transaction was co-led by partners Philip Broke and Sonica Tolani and included associates Caoimhin Eastwood and Ciara Lamph. The team was also supported by colleagues across the Firm’s Financial Services Regulatory, Antitrust, Foreign Direct Investment, Incentives and Finance practices.

    Press contact
    For more information please speak to your local media contact.

    Continue Reading

  • Jacobs to Acquire Remaining Stake in PA Consulting

    Jacobs to Acquire Remaining Stake in PA Consulting

    DALLAS, Jan. 5, 2026 /PRNewswire/ – Jacobs (NYSE: J) and PA Consulting, a leading innovation and transformation consultancy, have reached an agreement for Jacobs to acquire the remaining stake in PA Consulting, which is primarily held by PA existing and former employees. Jacobs’ further investment in PA creates a global advisory powerhouse for clients – delivering solutions that enhance capital efficiency, accelerate innovation and drive lasting value.  

    The total upfront consideration for the remaining stake will be approximately £1.216 billion ($1.6 billion), reflecting a valuation for 100% of the business of approximately £3.05 billion, or 13.0x expected calendar year 2025 adjusted EBITDA2 before synergies, and 12.3x including estimated synergies. The transaction also includes £75 million in deferred consideration which is expected to be paid in Jacobs’ shares valued on the second anniversary of the transaction closing. The transaction has been unanimously approved by Jacobs’ Board of Directors and PA’s Stakeholder Representatives. PA’s Stakeholder Representatives and members of the key leadership team have given irrevocable undertakings to vote in favor of the transaction.

    Jacobs Chair and CEO Bob Pragada said: “Since our strategic investment in March 2021, our collaboration with PA Consulting has accelerated profitable growth and reinforced Jacobs’ leadership as we redefine the asset lifecycle — embedding us earlier in client journeys and expanding our impact across strategy, transformation and advisory. Jacobs’ deep understanding of infrastructure delivery, capital asset cycles and highly technical program management complement PA Consulting’s strategic advisory, innovation and transformation capabilities – together enabling us to transform bold ideas into practical, optimized outcomes for our clients.”

    “This is a key milestone for our business and underscores our disciplined approach for return-focused capital allocation and our priority to drive sustained value creation,” Pragada added. “Our partnership during the past 4+ years demonstrates we are positioned to enhance Jacobs’ margin profile even further and unlock synergies, including new cross-sell opportunities.”

    PA Consulting CEO Christian Norris said: “By fully bringing together the expertise of PA and Jacobs, we can better empower clients to overcome today’s complexities and embrace tomorrow’s opportunities with confidence. We know that, together, we’re making a positive difference to businesses, economies and societies. Investing and extending PA’s valuable brand and positioning in innovation and transformation consulting will enable us to tackle the broadest range of client challenges. Looking ahead, I’m excited to build on what we’ve achieved for clients so far and deliver even greater impact as one global company.”

    Strategic and Financial Rationale for the Combination 

    The transaction represents the next step in the collaboration between Jacobs and PA Consulting and is expected to bring multiple strategic and financial benefits:

    • Strengthen end-to-end asset lifecycle: Combined business enhances Jacobs’ ability to deliver full asset lifecycle from front-end strategy and design through build, operations and maintenance, positioning Jacobs as a more comprehensive partner to clients.
    • Expand presence in high-growth, resilient sectors: Full ownership of PA strengthens Jacobs’ presence in high-growth and historically resilient sectors such asadvanced manufacturing, life sciences and critical infrastructure, including energy andtransportation. The transaction will also expand participation in advisory and AI/digital projects. Together, Jacobs and PA will accelerate AI business transformation across the enterprise, both internally and externally for clients.
    • Enhance go-to-market value proposition: Full ownership will enable broader and more integrated collaboration in pursuit of joint bids which is expected to accelerate our current positive momentum in both the volume and win rates for joint business opportunities.
    • Bring complementary capabilities to clients: PA’s strategic advisory and data analysis capabilities are highly complementary to Jacobs’ project management and technical engineering tool kit and together the combined company will be well-positioned to capture the increasing demand from clients who require a more comprehensive and consultative provider of solutions. The combined capabilities are particularly well-suited for the wave of investment in AI data centers, power generation, regionalized supply chains, advanced pharmaceutical facilities and critical infrastructure resilience.
    • Streamlined governance and decision-making structure: The combined company will benefit from simpler governance and operations, streamlined decision-making, and realization of synergies. Integration process will be staged to build on successful collaboration to date, all while maintaining sales momentum.
    • Drives higher margins, accretion to EPS and strong returns: Transaction is expected to increase Jacobs’ adjusted EBITDA margin3 post-close. For reference, had Jacobs fully owned PA Consulting for all of FY25, our adjusted EBITDA margin would have been 14.5% compared to our actual adjusted EBITDA margin3 of 13.9%. Expected cost synergies of £12-15 million are targeted to be realized within 24 months post close. The transaction is expected to be accretive to adjusted EPS in the first 12 months after closing.2

    Transaction Terms and Financing

    The transaction is structured with Jacobs acquiring the remaining stake of PA Consulting, which is primarily held by PA existing and former employees, for upfront consideration of approximately £1.216 billion, which is inclusive of expected adjustments up through the anticipated closing date. The upfront consideration, net of certain transaction expenses payable by the shareholders, will be paid 80% in cash and 20% in Jacobs’ shares. 

    The transaction also includes deferred consideration of £75 million which is payable in Jacobs’ shares as valued on the two-year anniversary following closing, cash, or a combination thereof, at Jacobs’ election. Jacobs intends to fund the cash portion of the upfront consideration through a combination of cash-on-hand and existing and incremental debt facilities.

    The transaction will primarily be implemented by way of a U.K. Scheme of Arrangement and is subject to the satisfaction of customary closing conditions, including the approval of the current shareholders of PA and the U.K. Court (pursuant to the Scheme). The transaction is expected to close by the end of Jacobs’ fiscal 2026 second quarter.

    Advisors

    Centerview Partners LLC and Perella Weinberg Partners LP are serving as financial advisors and Akin Gump LLP is serving as legal counsel to Jacobs. 

    Goldman Sachs is serving as financial advisor and Milbank LLP is serving as legal counsel to PA Consulting. 


    [1] Based on the currency exchange rate of 1.33 USD to GBP.

    [2] Reconciliation of the expected accretion of the transaction to Jacobs adjusted EPS in the first 12 months after close and expectations for PA Consulting’s calendar year 2025 adjusted EBITDA before and including synergies to the most directly comparable GAAP measures are not available without unreasonable efforts because we cannot predict with sufficient certainty all the components required to provide such reconciliations.

    [3] See Non-GAAP Financial Measures and GAAP Reconciliations at the end of the press release for additional detail. 

    About Jacobs

    At Jacobs, we’re challenging today to reinvent tomorrow – delivering outcomes and solutions for the world’s most complex challenges. With approximately $12 billion in annual revenue and a team of almost 43,000, we provide end-to-end services in advanced manufacturing, cities & places, energy, environmental, life sciences, transportation and water. From advisory and consulting, feasibility, planning, design, program and lifecycle management, we’re creating a more connected and sustainable world. See how at jacobs.com and connect with us on LinkedIn, Instagram, X and Facebook. 

    About PA Consulting 

    PA Consulting accelerates new growth ideas from concept, through design and development and to commercial success, and revitalizes organizations, building leadership, culture, systems and processes to make innovation a reality. PA Consulting’s global team of about 4,000, which includes strategists, innovators, designers, consultants, digital experts, scientists, engineers and technologists, work across seven sectors: consumer and manufacturing, defense and security, energy and utilities, financial services, government, health and life sciences, and transport to make a positive impact alongside the clients it supports, bringing ingenuity to life. PA Consulting operates globally from offices across the U.K., U.S., Europe, including in the Nordics and Netherlands.

    Additional Information

    Additional information regarding the transaction is available on our investor relations page at https://invest.jacobs.com. 

    The new Jacobs shares to be issued in connection with the transaction have not been registered under the U.S. Securities Act of 1933, as amended (U.S. Securities Act), and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act. The new Jacobs shares to be issued in connection with the transaction will be issued pursuant to one or more exemptions from registration under the U.S. Securities Act. 

    Neither the U.S. Securities and Exchange Commission (SEC) nor any U.S. state securities commission has approved or disapproved of the new Jacobs shares to be issued in connection with the transaction or determined if this release is accurate or complete. Any representation to the contrary is a criminal offence in the United States.

    This release is for information purposes only and is not intended to and does not constitute, or form any part of, an offer, invitation or the solicitation of an offer to purchase or subscribe, otherwise acquire, subscribe for, sell or otherwise dispose of any securities or the solicitation of any vote or approval in any jurisdiction in connection with the transaction or otherwise.

    # # #

    Forward-Looking Statements

    Certain statements contained in this press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that do not directly relate to any historical or current fact. When used herein, words such as “expects,” “anticipates,” “believes,” “seeks,” “estimates,” “plans,” “intends,” “future,” “will,” “would,” “could,” “can,” “may,” and similar words are intended to identify forward-looking statements. Examples of forward-looking statements include, but are not limited to, statements we make concerning our plans to acquire the remaining stake in PA Consulting, the potential strategic and financial rationale for the proposed transaction, including the amount of expected synergies and the time period in which such synergies will be achieved, the future financial and operating results of the combined company, the growth opportunities and strategic benefits, the expected timing and structure of the proposed transaction, the expectation that the transaction will be accretive to adjusted earnings per share in 12 months, the ability of the parties to complete the proposed transaction, and any assumptions underlying any of the foregoing. We base these forward-looking statements on management’s current estimates and expectations, as well as currently available competitive, financial and economic data. Forward-looking statements, however, are inherently uncertain. There are a variety of factors that could cause business results to differ materially from our forward-looking statements including, but not limited to, uncertainties as to, the possibility that the closing conditions for the proposed transaction may not be satisfied or waived, on a timely basis or otherwise; the risks that any consents or approvals, including any regulatory approvals, required in connection with the proposed transaction may not be received; the risk that the proposed transaction may not be completed on the terms or in the time-frame expected by the parties; unexpected costs, liabilities, charges or expenses related to the proposed transaction and the actual terms of any financings that will be obtained for the transaction; our ability to successfully integrate PA Consulting into our business, our ability to realize the estimated synergies of the proposed transaction; our ability to retain and hire key personnel, customers or suppliers while the proposed transaction is pending or after it is completed; as well as other factors that may impact us, such as competition from existing and future competitors in our target markets, financial market risks to us, including by affecting our access to capital, timing of the award of projects and funding and potential changes to governmental priorities and reduction in governmental spending, changes in U.S. or foreign tax laws, including the tax legislation enacted in the U.S. in July 2025, statutes, rules, regulations or ordinances, including the impact of, and changes to tariffs and retaliatory tariffs or trade policies, that may adversely impact our future financial positions or results of operations, as well as general economic conditions, including inflation and the actions taken by monetary authorities in response to inflation, changes in interest rates and foreign currency exchange rates, changes in capital markets, the possibility of a recession or economic downturn, and increased uncertainty and risks, including policy risks and potential civil unrest, relating to the outcome of elections across our key markets and elevated geopolitical tension and conflicts, among others. For a description of these and additional factors that may occur that could cause actual results to differ from our forward-looking statements, see our filings with the U.S. Securities and Exchange Commission. The company is not under any duty to update any of the forward-looking statements after the date of this press release to conform to actual results, except as required by applicable law.

    Non-GAAP Financial Measures 

    In this press release, Jacobs has included certain non-GAAP financial measures as defined in Regulation G promulgated under the Securities Exchange Act of 1934, as amended. These non-GAAP measures are described below. 

    Adjusted net revenue is calculated by adjusting revenue from continuing operations to exclude amounts we bill to clients on projects where we are procuring subcontract labor or third-party materials and equipment on behalf of the client (referred to as “pass throughs”). These amounts are considered pass throughs because we receive no or only a minimal mark-up associated with the billed amounts. In 2023, we amended our name and convention for revenue, excluding pass-through costs from “net revenue” to “adjusted net revenue.” This name change is intended to make the non-GAAP nature of this measure more prominent and does not impact measurement. We sometimes refer to our GAAP revenue as “gross revenue”. 

    Jacobs adjusted earnings from continuing operations before taxes, adjusted income tax expenses from continuing operations, adjusted net earnings from continuing operations and adjusted EPS from continuing operations are calculated by: 

    1. Excluding items collectively referred to as Restructuring, Transaction and Other Charges, which include:
      1. transaction costs and other charges incurred in connection with mergers, acquisitions, strategic investments and divestitures, including advisor fees, change in control payments, and the impact of the quarterly adjustment to the estimated performance based payout of contingent consideration to certain sellers in connection with certain acquisitions and similar transaction costs and expenses (collectively referred to as “Transaction Costs”);
      2. recoveries, costs and other charges associated with (i) restructuring activities, (ii) cost reduction initiatives implemented in connection with mergers, acquisitions, strategic investments and divestitures, including the separation of the CMS/C&I business, such as advisor fees, involuntary terminations and related costs, costs associated with co-locating offices of acquired companies, separating physical locations of continuing operations, professional services and other personnel costs, (iii) involuntary termination programs and other related separations impacting management and employees, including related transition costs, and (iv) certain legal costs and expenses to the extent related to (i) – (iii) or determined to not be related to continuing operations (clauses (i) – (iv) collectively referred to as “Restructuring, integration, separation and other charges”).

     

    1. Excluding items collectively referred to as “Other adjustments”, which include:
      1. intangible assets amortization and impairment charges;
      2. impact of certain subsidiary level contingent equity-based agreements in connection with the transaction structure of our PA Consulting investment;
      3. impacts related to tax rate increases in the UK in a prior period;
      4. revenue under the Company’s transition services agreement (TSA) included in other income for U.S. GAAP reporting purposes, and any SG&A costs associated with the provision of such services;
      5. pretax mark-to-market and other related gains or losses associated with the Company’s investment in Amentum stock recorded in connection with the Separation Transaction;
      6. discounts and expenses related to the one-time exchange of the Company’s investment in Amentum shares for a portion of the Company’s outstanding term loans, which term loans were canceled; and
      7. impacts resulting from the EPS numerator adjustment relating to the redeemable noncontrolling interests preference share repurchase and reissuance activities.

    We eliminate the impact of “Restructuring, Transaction and Other Charges” and “Other Adjustments” because we do not consider these to be indicative of ongoing operating performance. Actions taken by the company to enhance efficiencies are subject to significant fluctuations from period to period. Jacobs’ management believes the exclusion of the amounts relating to the above-listed items improves the period-to-period comparability and analysis of the underlying financial performance of the business.

    Adjustments to derive adjusted net earnings from continuing operations and adjusted EPS from continuing operations are calculated on an after-tax basis.

    Adjusted EBITDA is calculated by adding income tax expense, depreciation expense and interest expense to, and deducting interest income from, adjusted net earnings attributable to Jacobs from continuing operations. 

    We believe that the measures listed above are useful to management, investors and other users of our financial information in evaluating the announced transaction by excluding or adding back the effects of the items described above and below, the inclusion or exclusion of which can obscure underlying trends. Additionally, management uses such measures in its own evaluation of Jacobs’ performance, particularly when comparing performance to past periods, and believes these measures are useful for investors because they facilitate a comparison of our financial results from period to period.

    This press release also contains certain financial and operating metrics which management believes are useful in evaluating the announced transaction. Adjusted EBITDA margin refers to a ratio of adjusted EBITDA to adjusted net revenue. 

    Jacobs provides non-GAAP measures to supplement U.S. GAAP measures, as they provide additional insight into Jacobs’ financial results. However, non-GAAP measures have limitations as analytical tools and should not be considered in isolation and are not in accordance with, or a substitute for, U.S. GAAP measures. In addition, other companies may define non-GAAP measures differently, which limits the ability of investors to compare non-GAAP measures of Jacobs to those used by our peer companies.

    The following tables reconcile the components and values of U.S. GAAP revenue from continuing operations to adjusted net revenue from continuing operations and Net Earnings Attributable to Jacobs from Continuing Operations to Adjusted EBITDA. For the comparable period presented below, such adjustments consist of amounts incurred in connection with the items described above. Amounts are shown in thousands.

     

    Reconciliation of Revenue from Continuing Operations to Adjusted Net Revenue from Continuing Operations (in thousands): 

     

     

    Fiscal Year Ended

    September 26, 2025

    Revenue from Continuing Operations  $           12,029,783
       
    Pass Through Revenue (3,334,818)
       
    Adjusted Net Revenue from Continuing Operations $             8,694,965

     

    Reconciliation of Net Earnings Attributable to Jacobs from Continuing Operations to Adjusted EBITDA (in thousands):

     

     

    Fiscal Year Ended

    September 26, 2025

    Net Earnings Attributable to Jacobs from Continuing Operations $              313,302 
       
    After-tax effects of Restructuring, Transaction and Other Charges                       43,956 
    After-tax effects of Other Adjustments                     388,357 
       
    Adj. Net Earnings Attributable to Jacobs from Continuing Operations                     745,615 
       
    Adj. Income Tax Expense from Continuing Operations                    268,885 
       
    Adj. Earnings from Continuing Operations attributable to Jacobs before Taxes                 1,014,500 
       
    Depreciation expense                      82,059 
    Interest income                    (35,804)
    Interest expense                    145,788 
       
    Adjusted EBITDA $            1,206,543 
       
      Adjusted EBITDA Margin 13.9%
       
     Addback to Adjusted EBITDA to eliminate Redeemable Noncontrolling Interests attributable to PA                        52,321 
       
    Adjusted EBITDA – adjusted to illustrate 100% ownership of PA for FY25  $           1,258,864 
       
      Adjusted EBITDA Margin 14.5%

     

    Reconciliation of Earnings from Continuing Operations Before Taxes to Adjusted Earnings from Continuing Operations Attributable Before Taxes (in thousands):

     

     

    Fiscal Year Ended

    September 26, 2025

    Earnings from Continuing Operations Before Taxes $               543,477 
       
    Restructuring, Transaction and Other Charges(1):  
       Transaction costs                             64 
       Restructuring, integration, separation and other charges                      61,316 
       
    Other Adjustments(2):  
       Transition Services Agreement, net                    (14,475)
       Amortization of intangibles                   155,517 
       Mark-to-market and other related (gains) losses on investment in Amentum stock                   227,305 
       Other                      97,060 
    Adjusted Earnings from Continuing Operations Before Taxes                1,070,264 
       
    Adjusted Earnings Attributable to Noncontrolling Interests from Continuing Operations                    (55,764)
       
    Adj. Earnings from Continuing Operations attributable to Jacobs before Taxes $          1,014,500 

     

     

    (1) Includes pre-tax charges primarily relating to the Separation Transaction, as well as charges associated with various transaction costs and activity associated with Jacobs’ restructuring and integration programs.

    (2) Includes pre-tax charges relating to amortization of intangible assets and the impact of certain subsidiary level compensation based agreements, pretax mark-to-market gains and losses associated with our investment in Amentum stock in connection with the Separation Transaction, income under Jacob’s TSA with Amentum in connection with the Separation Transaction and discounts and expenses associated with Jacobs’ non-cash equity for debt exchange transacted on March 13, 2025.

     

    Reconciliation of Income Tax Expense from Continuing Operations to Adjusted Income Tax Expense from Continuing Operations (in thousands):

     

     

    Fiscal Year Ended

    September 26, 2025

    Income Tax Expense for Continuing Operations $               (215,555)
    Tax Effects of Restructuring, Transaction and Other Charges(1)  
    Transaction costs                             83
    Restructuring, integration, separation and other charges                    (16,949)
       
    Tax Effects of Other Adjustments(2)  
    Transition Services Agreement, net                        3,691
    Amortization of intangibles                    (39,776)
    Other                          (379)
       
    Adjusted Income Tax Expense from Continuing Operations $               (268,885)

     

     

    (1) Includes income tax impacts on restructuring activities primarily relating to the Separation Transaction as well as charges associated with various transaction costs and activity associated with Jacobs’ restructuring and integration programs.

    (2) Includes income tax impacts on amortization of intangible assets, certain subsidiary level compensation-based agreements, income under Jacobs’ TSA with Amentum in connection with the Separation Transaction and discounts and expenses associated with Jacobs’ non-cash equity for debt exchange transacted on March 13, 2025.

    For additional information contact: 

    Investors: 

    Bert Subin
    JacobsIR@jacobs.com 


    Continue Reading